Brief: Checkpoint Therapeutics Announces Publication Of Cosibelimab Pivotal Trial Results
18/10/2023 13:36
Oct 18 (Reuters) - Checkpoint Therapeutics Inc CKPT.O :
* CHECKPOINT THERAPEUTICS ANNOUNCES PUBLICATION OF
COSIBELIMAB
PIVOTAL TRIAL RESULTS IN THE JOURNAL FOR IMMUNOTHERAPY OF CANCER
* CHECKPOINT THERAPEUTICS INC - BIOLOGICS LICENSE
APPLICATION
REVIEW ONGOING; PDUFA GOAL DATE OF JANUARY 3, 2024
Source text for Eikon: ID:nGNX2FWjT0
Further company coverage: CKPT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Checkpoint Therapeutics
See all newsCheckpoint Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Checkpoint Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Checkpoint Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Checkpoint Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview
Street View -India's Sun Pharma buying Checkpoint boosts its specialty portfolio, analysts say